Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 549 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT06698458Recruiting
DaRT radiation plus chemo for advanced pancreatic cancer
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–120 - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT04212715RecruitingPhase 2
Extra radiation boost for high-risk prostate cancer
This Phase 2 study tests a treatment plan that uses standard focused radiation to the prostate, plus an extra “boost” delivered inside the prostate. It may help improve control of high-risk prostate cancer, especially by aiming radiation more precisely.
RiyadhAges 18–99 - NCT07802704RecruitingPhase 3
Study of risvutatug rezetecan for advanced prostate cancer
This trial tests an experimental drug called Risvutatug Rezetecan for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The drug works by targeting cancer cells and delivering a toxic agent directly to them, potentially slowing the cancer's growth.
Auchenflower, QueenslandAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT05613023RecruitingPhase 3
Short-course prostate and pelvic SBRT using 5 treatment sessions
This study compares two schedules of highly focused radiation (SBRT): 5 sessions to the prostate only, versus 5 sessions to the prostate and nearby pelvic lymph nodes. It aims to see which approach controls high-risk localized prostate cancer better while you also take hormone therapy.
CorkAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT07395804Recruiting
How darolutamide works for advanced prostate cancer in Germany
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
LocationsAges 18 years+ - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Antioch, CaliforniaAges 18 years+ - NCT06689163RecruitingPhase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Hefei, AnhuiAges 18 years+ - NCT06638541Recruiting
Lowering radiation dose for prostate cancer using MRI-guided machine
This trial tests if giving fewer radiation treatments using a special MRI-guided machine is safe and effective for men with prostate cancer. It may help reduce side effects while still controlling the cancer.
TorontoAges 18 years+ - NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT06758882RecruitingPhase 2
Surgery with or without apalutamide for high-risk prostate cancer that has spread a little
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Torino, ToAges 18–80 - NCT06917781Recruiting
Prostate cancer blood test vs. PSMA-PET scan study
This study is checking how well a blood test (liquid biopsy) can find prostate cancer and compare it to a special PET scan (PSMA-PET). If you qualify, you might help improve how we track prostate cancer without needing more invasive biopsies.
ToulouseAges 18 years+ - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 549 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.